European Heart Journal Advance Access originally published online on November 15, 2005
European Heart Journal 2006 27(3):255-257; doi:10.1093/eurheartj/ehi652
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Are vascular function measurements ready for the clinic?
1Cardiovascular Medicine Division, Stanford University Medical Center, Stanford, CA, USA
2Department of Medicine, University of Melbourne, St Vincent's Hospital, Melbourne, Australia
* Corresponding author. Tel: +1 650 723 6141; fax: +1 650 725 1599. E-mail address: awilson{at}cvmed.stanford.edu
This editorial refers to ‘Flow-mediated changes in pulse wave velocity: a new clinical measure of endothelial function’
by K.K. Naka et al., on page 302
The relevance of vascular function assessments to clinical medicine
Changes in vascular function such as endothelial function and arterial stiffness are key early features in the development of human cardiovascular disease, and non-invasive measures of vascular function have been utilized extensively in clinical research. Many non-invasive indices correlate well with more direct and invasive measures and thus can be applied to large cohorts, potentially outside of a laboratory. As some of these techniques are now available for use outside of a research setting, the clinician is increasingly forced to assess their various merits and the relevance of specific findings in individual patients. Although it is logical to suggest that they may, whether such strategies translate into reduced cardiovascular disease morbidity and mortality in a clinical setting is largely unknown.
Abnormalities can be seen in measures of endothelial function and/or arterial stiffness before overt cardiovascular disease develops and are seen in subjects with or at high risk of developing vascular disease, including subjects with hypercholesterolaemia, hypertension, diabetes, and chronic renal failure. Thus, it is hoped that screening such subjects may direct early targeted intervention. Cross-sectional studies have shown how novel and traditional risk factors interact in determining vascular dysfunction and atherosclerosis. In addition, abnormalities in some vascular assessments provide prognostic data independent of and additive to more well-established risk factors and they are also able to act as surrogate measures in intervention studies because some cardiovascular therapies can lead to early and lasting improvements in measured vascular function. For example, it has been suggested that blood pressure ‘independent’ effects of therapies such as angiotensin-converting enzyme inhibitors seen in large-scale interventional studies may, in fact, be a manifestation of improvements in arterial stiffness indices.1
The endothelium plays a key role in vascular homeostasis regulating vascular tone, smooth muscle cell proliferation and migration, and fibrinolysis as well as interactions between the vessel wall, platelets, and leukoctyes. Endothelial production of nitric oxide (NO) is central to this function, and abnormalities in NO generation and stability are well described at all stages of atherosclerosis. Endothelial function can be measured non-invasively in the brachial artery (FMD)2 using high definition ultrasound that assesses the change in arterial diameter in response to altered flow, an effect which has been shown to be dependent on local NO generation. This measure is used to some extent as a surrogate measure of other endothelial functions. The technique of brachial artery FMD measurement is limited as a tool in direct patient care because it requires a trained operator, a regulated environment, and specialized equipment, ideally including high definition ultrasound, archiving of studies and edge-tracking software. Thus, its role is currently mainly limited to a valuable one in the clinical research setting.3
The peripheral arterial waveform represents a combination of the anterograde systolic wave and reflected waves. Arterial stiffening is associated with increased velocity of the transmitted arterial pulse wave and altered interaction between anterograde and reflected waves with reflected waves interacting earlier (in systole) with the incident wave, contributing to systolic hypertension, decreased diastolic pressure, and thus an increased pulse pressure. Arterial stiffness is determined by a combination of factors including structural characteristics of the vascular wall and dynamic forces impacting on arterial wall tone. Central arterial stiffening is associated with normal ageing but also with a range of disease states, such as hypertension and diabetes. Processes such as vascular calcification and deposition of advanced glycation end-products, such as occur in diabetes and lead to increased collagen cross-linking, are implicated in accelerated arterial stiffening. In peripheral muscular arteries, vascular tone variations, particularly relating to altered flow and endothelial NO production, also impact on measured stiffness indices.4
The simplest surrogate measure of central arterial stiffness in clinical practice is pulse pressure, although it has been demonstrated that brachial pulse pressure may not fully or accurately represent central pulse pressure. Nevertheless, elevated brachial pulse pressure has been shown to be an important independent predictor of events, particularly in older subjects, such as in the Framingham cohort study.5 Some other available techniques aim to provide an overall estimate of arterial stiffness and rely on a peripheral non-invasive measurement such as with arterial tonometry.6 Indices that can be derived include pulse-wave velocity (PWV) and systolic pulse-wave augmentation, largely a manifestation of PWV. More complex techniques rely on modelling the arterial circulation such as with a modified Windkessel model and assess the effect of increased stiffness on the arterial waveform at various points in the arterial circulation.7 This area is made complex for the clinician by the growth of available techniques, differences in terminology, and lack of available reference values.8
Importantly, there is no measure that gives a complete and definitive assessment of vascular health and there is great controversy about the relative validity and utility of some models and techniques. Features such as the heterogeneity of atherosclerosis throughout the arterial tree, the effects of pulse-wave augmentation and of branch points are difficult to account for in a global model of the arterial circulation. There is also a significant degree of theoretical overlap between various measures. For example, as NO appears to regulate arterial stiffness, particularly in small vessels,9 some of these indices appear at least partly dependent on the function of the endothelium, such as the technique described by Naka et al.10
Measuring endothelial function in clinical practice
Naka et al.10 describe a novel technique for assessing ‘endothelial function’ which assesses the effects of altered distal flow on measured PWV in two subject groups, healthy controls, and patients with congestive heart failure, a condition associated with impaired endothelial function. Having established that PWV was reduced by intra-arterial acetylcholine and increased by the NO-inhibitor N-monomethyl-L-arginine, they found that reactive hyperaemia was associated with reduced PWV in controls but not in congestive heart failure patients, suggestive that the capacity to alter PWV with altered flow was lost in those subjects with endothelial dysfunction. Their technique supports the concept that at a practical level, there is overlap between a non-invasive measure of peripheral endothelial function and arterial stiffness, manifested by increased PWV. Unfortunately, there was no direct correlation between this measure and FMD presented. This is important as there have been relatively few studies directly comparing a range of techniques to each other in the same subjects11 and the extent to which abnormalities in one measure represent those in others is largely unknown. For these techniques to be broadly applied in the clinical setting and aid in guiding therapy, this issue needs to be clarified because there is currently no real ‘gold standard’ measure of vascular function.
Use of vascular assessments in the clinic
Much of the data available about vascular function assessment has been collected during clinical research studies in a controlled environment, such as the study by Naka et al. Most studies are performed in steady state conditions at a standardized time (usually morning) after an overnight fast with medications, cigarettes, and caffeine withheld for a defined period prior to testing. Many factors, including the use of vasoactive medications, diurnal variation, fasting state, and exercise prior to testing, appear to cause acute and significant changes in many non-invasive measures of vascular function. Attention to these issues is crucial if these tools are to be employed for serial measurements in an individual over time and/or to assess the effects of therapies. Also, highly relevant is the issue of operator training and experience. It is reasonable to expect a degree of inaccuracy with many techniques when used by inexperienced operators or in a clinic setting where many operators may test the same patient. Thus, available measures should be standardized as much as possible.
Non-invasive measurement of vascular function can provide prognostic information and has the potential to guide the care of patients with or at risk of cardiovascular disease. However, for these studies to be become accepted into mainstream clinical practice, evidence needs to be shown that their use in guiding therapy leads to improved outcomes for patients in prospective studies over and above information gained by targeting blood pressure and lipid levels. Until the results of such studies are known, the role of these assessments appears to be primarily a valuable one in clinical research.
Supported in part by the National Heart Foundation of Australia and the National Health and Medical Research Council of Australia.
Conflict of interest: none declared.
Footnotes
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
doi:10.1093/eurheartj/ehi619 
References
- Asmar R, Topouchian J, Pannier B, Benetos A, Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001;19:813–818.[CrossRef][Web of Science][Medline]
- Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–1115.[CrossRef][Web of Science][Medline]
- Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–265.
[Abstract/Free Full Text] - Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, Ganz P. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001;38:1049–1053.
[Abstract/Free Full Text] - Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100:354–360.
[Abstract/Free Full Text] - Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989;80:1652–1659.
[Abstract/Free Full Text] - Finkelstein SM, Cohn JN. First- and third-order models for determining arterial compliance. J Hypertens Suppl 1992;10:S11–S14.[CrossRef][Medline]
- O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002;15:426–444.[CrossRef][Web of Science][Medline]
- McVeigh GE, Allen PB, Morgan DR, Hanratty CG, Silke B. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci (Lond) 2001;100:387–393.[Medline]
- Naka KK, Tweddel AC, Doshi SN, Goodfellow J, Henderson AH. Flow-mediated changes in pulse wave velocity: a new clinical measure of endothelial function. Eur Heart J 2006;27:302–309. First published on November 2, 2005, doi:10.1093/eurheartj/ehi619.
[Abstract/Free Full Text] - Wilson AM, O'Neal D, Nelson CL, Prior DL, Best JD, Jenkins AJ. Comparison of arterial assessments in low and high vascular disease risk groups. Am J Hypertens 2004;17:285–291.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Flow-mediated changes in pulse wave velocity: a new clinical measure of endothelial function
- Katerina K. Naka, Ann C. Tweddel, Sagar N. Doshi, Jonathan Goodfellow, and Andrew H. Henderson
EHJ 2006 27: 302-309.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. J. Bax, B. De Bruyne, A. K. Gitt, S. Kristensen, C. Linde, D. Poldermans, F. J. Pinto, P. Ponikowski, B. D. Prendergast, E. Abagiti-Rosei, et al. Highlights of the 2006 Scientific Sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006 J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2564 - 2574. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||